Standout Papers

Reduced cardiotoxicity and comparable efficacy in a phase IIItrial of pegylated liposomal doxor... 2004 2026 2011 2018 1.3k
  1. Reduced cardiotoxicity and comparable efficacy in a phase IIItrial of pegylated liposomal doxorubicin HCl(CAELYX™/Doxil®) versus conventional doxorubicin forfirst-line treatment of metastatic breast cancer (2004)
    E O’Brien, Nely Wigler et al. Annals of Oncology

Immediate Impact

7 by Nobel laureates 23 from Science/Nature 83 standout
Sub-graph 1 of 19

Citing Papers

Throughput-scalable manufacturing of SARS-CoV-2 mRNA lipid nanoparticle vaccines
2023 StandoutNobel
Cancer nanomedicine
2022 Standout
1 intermediate paper

Works of Craig Tendler being referenced

Reduced cardiotoxicity and comparable efficacy in a phase IIItrial of pegylated liposomal doxorubicin HCl(CAELYX™/Doxil®) versus conventional doxorubicin forfirst-line treatment of metastatic breast cancer
2004 Standout

Author Peers

Author Last Decade Papers Cites
Craig Tendler 912 274 122 695 636 25 2.5k
Stephen H. Wrzesinski 864 87 8 169 993 20 2.0k
Eleonora Simeoni 408 115 21 237 1230 32 2.5k
T. A. Waldmann 878 517 278 39 3097 48 4.7k
Kashi Javaherian 500 64 2 55 1146 39 4.4k
Hidetoshi Mori 1625 55 14 100 324 52 3.4k
Helen J. Mardon 221 58 19 101 1714 60 3.9k
Philip J. Gotwals 1088 239 43 205 1127 36 4.3k
Robert J. Melder 635 41 10 217 607 50 2.9k
Kathleen A. Fitzgerald 519 66 18 149 1925 18 2.9k
Beate Diefenbach 312 25 3 263 298 14 2.6k

All Works

Loading papers...

Rankless by CCL
2026